2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTsA living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).
Bin Riaz I, Naqvi S, He H, Siddiqi R, Asghar N, Ravi P, Hussain S, Singh P, Bryce A. A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC). Journal Of Clinical Oncology 2023, 41: 193-193. DOI: 10.1200/jco.2023.41.6_suppl.193.Peer-Reviewed Original ResearchProgression-free survivalMetastatic castration-sensitive prostate cancerAndrogen pathway inhibitorsMCSPC patientsTriplet regimensHazard ratioSignificant improved progression-free survivalCastration-sensitive prostate cancerImproved progression-free survivalSubgroup dataOverall patient populationTiming of metastasisConfidence intervalsVolume of diseaseMixed treatment comparisonEvidence synthesis frameworkSTAMPEDE trialTreatment intensificationTriplet regimenDisease volumeMetastatic presentationSystemic therapyOptimal therapyRandomized comparisonPatient population
2021
A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Maheswari D, Sipra Q, Montori V, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 335-335. DOI: 10.1200/jco.2021.39.6_suppl.335.Peer-Reviewed Original ResearchInteractive tableArtificial intelligenceJavaScript programming languageFive-layered architectureMetastatic renal cell carcinomaFirst-line metastatic renal cell carcinomaLine Metastatic Renal Cell CarcinomaProgramming languageProgression-free survivalDifferent teamsComplete responseOverall survivalSystematic reviewSearch strategyDynamic featuresNetworkEvidence synthesisInteractive networkFirst-line treatmentEvidence mapRenal cell carcinomaFrameworkShared-decision makingOverall responseBaseline characteristics